Thus, before undertaking clinical trials in patients, it would be advisable to cover additional aspects of molecular impact, for example, an analysis of the neuroprotective effects of 2-APB in animals with suppression or knockdown of Cx36 [60], TRPM2 [72], or TRPM7 [73], all of which are naturally protected from brain ischemia. Here, GJD2 is linked to brain ischemia.